Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 1999 Jun 15;340(Pt 3):703–709.

Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein.

D J Watson 1, D J Selkoe 1, D B Teplow 1
PMCID: PMC1220301  PMID: 10359654

Abstract

Hereditary cerebral haemorrhage with amyloidosis, Dutch type (HCHWA-D), is a cerebral amyloidosis characterized by prominent vascular deposits and fatal haemorrhages. The disorder is caused by a point mutation in codon 693 of the gene encoding the amyloid precursor protein (APP), resulting in a Glu-->Gln amino acid substitution at position 22 of the amyloid beta-protein (Abeta) region. The pathogenetic mechanisms of HCHWA-D are unknown but could involve alterations in the proteolytic processing of APP and in amyloid fibril formation. We examined Abeta production and stability by using cultured human embryonic kidney 293 cells stably expressing wild-type or 'Dutch' APP. Radiosequencing and quantitative immunoprecipitation experiments showed that cells expressing Dutch APP secreted increased quantities of Abeta peptides beginning at Asp1, and of truncated peptides beginning at Val18 and Phe19. The ratio of levels of 4 kDa (Abeta) to 3 kDa (p3) peptides remained constant due to co-ordinate decreases in other peptide species. Novel truncated or elongated peptides were not observed. Pulse-chase experiments showed that the Dutch mutation did not affect the stability of the Abeta or p3 populations. These results are consistent with a disease process in which the Dutch mutation results in the production of Abeta peptides with enhanced propensities for fibrillogenesis, leading to accelerated vascular deposition and disease.

Full Text

The Full Text of this article is available as a PDF (183.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cai X. D., Golde T. E., Younkin S. G. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science. 1993 Jan 22;259(5094):514–516. doi: 10.1126/science.8424174. [DOI] [PubMed] [Google Scholar]
  2. Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A. Y., Seubert P., Vigo-Pelfrey C., Lieberburg I., Selkoe D. J. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature. 1992 Dec 17;360(6405):672–674. doi: 10.1038/360672a0. [DOI] [PubMed] [Google Scholar]
  3. Citron M., Vigo-Pelfrey C., Teplow D. B., Miller C., Schenk D., Johnston J., Winblad B., Venizelos N., Lannfelt L., Selkoe D. J. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):11993–11997. doi: 10.1073/pnas.91.25.11993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Clements A., Allsop D., Walsh D. M., Williams C. H. Aggregation and metal-binding properties of mutant forms of the amyloid A beta peptide of Alzheimer's disease. J Neurochem. 1996 Feb;66(2):740–747. doi: 10.1046/j.1471-4159.1996.66020740.x. [DOI] [PubMed] [Google Scholar]
  5. Clements A., Walsh D. M., Williams C. H., Allsop D. Effects of the mutations Glu22 to Gln and Ala21 to Gly on the aggregation of a synthetic fragment of the Alzheimer's amyloid beta/A4 peptide. Neurosci Lett. 1993 Oct 14;161(1):17–20. doi: 10.1016/0304-3940(93)90129-9. [DOI] [PubMed] [Google Scholar]
  6. Cras P., van Harskamp F., Hendriks L., Ceuterick C., van Duijn C. M., Stefanko S. Z., Hofman A., Kros J. M., Van Broeckhoven C., Martin J. J. Presenile Alzheimer dementia characterized by amyloid angiopathy and large amyloid core type senile plaques in the APP 692Ala-->Gly mutation. Acta Neuropathol. 1998 Sep;96(3):253–260. doi: 10.1007/s004010050892. [DOI] [PubMed] [Google Scholar]
  7. De Jonghe C., Zehr C., Yager D., Prada C. M., Younkin S., Hendriks L., Van Broeckhoven C., Eckman C. B. Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. Neurobiol Dis. 1998 Oct;5(4):281–286. doi: 10.1006/nbdi.1998.0202. [DOI] [PubMed] [Google Scholar]
  8. Dovey H. F., Suomensaari-Chrysler S., Lieberburg I., Sinha S., Keim P. S. Cells with a familial Alzheimer's disease mutation produce authentic beta-peptide. Neuroreport. 1993 Aug;4(8):1039–1042. doi: 10.1097/00001756-199308000-00011. [DOI] [PubMed] [Google Scholar]
  9. Eckman C. B., Mehta N. D., Crook R., Perez-tur J., Prihar G., Pfeiffer E., Graff-Radford N., Hinder P., Yager D., Zenk B. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). Hum Mol Genet. 1997 Nov;6(12):2087–2089. doi: 10.1093/hmg/6.12.2087. [DOI] [PubMed] [Google Scholar]
  10. Enya M., Morishima-Kawashima M., Yoshimura M., Shinkai Y., Kusui K., Khan K., Games D., Schenk D., Sugihara S., Yamaguchi H. Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging. Am J Pathol. 1999 Jan;154(1):271–279. doi: 10.1016/s0002-9440(10)65273-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Esch F. S., Keim P. S., Beattie E. C., Blacher R. W., Culwell A. R., Oltersdorf T., McClure D., Ward P. J. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science. 1990 Jun 1;248(4959):1122–1124. doi: 10.1126/science.2111583. [DOI] [PubMed] [Google Scholar]
  12. Fabian H., Szendrei G. I., Mantsch H. H., Otvos L., Jr Comparative analysis of human and Dutch-type Alzheimer beta-amyloid peptides by infrared spectroscopy and circular dichroism. Biochem Biophys Res Commun. 1993 Feb 26;191(1):232–239. doi: 10.1006/bbrc.1993.1207. [DOI] [PubMed] [Google Scholar]
  13. Felsenstein K. M., Lewis-Higgins L. Processing of the beta-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation. Neurosci Lett. 1993 Apr 2;152(1-2):185–189. doi: 10.1016/0304-3940(93)90514-l. [DOI] [PubMed] [Google Scholar]
  14. Fraser P. E., Nguyen J. T., Inouye H., Surewicz W. K., Selkoe D. J., Podlisny M. B., Kirschner D. A. Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid beta-protein. Biochemistry. 1992 Nov 10;31(44):10716–10723. doi: 10.1021/bi00159a011. [DOI] [PubMed] [Google Scholar]
  15. Gowing E., Roher A. E., Woods A. S., Cotter R. J., Chaney M., Little S. P., Ball M. J. Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J Biol Chem. 1994 Apr 15;269(15):10987–10990. [PubMed] [Google Scholar]
  16. Haass C., Hung A. Y., Selkoe D. J., Teplow D. B. Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. J Biol Chem. 1994 Jul 1;269(26):17741–17748. [PubMed] [Google Scholar]
  17. Haass C., Schlossmacher M. G., Hung A. Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B. L., Lieberburg I., Koo E. H., Schenk D., Teplow D. B. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 1992 Sep 24;359(6393):322–325. doi: 10.1038/359322a0. [DOI] [PubMed] [Google Scholar]
  18. Hendriks L., van Duijn C. M., Cras P., Cruts M., Van Hul W., van Harskamp F., Warren A., McInnis M. G., Antonarakis S. E., Martin J. J. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet. 1992 Jun;1(3):218–221. doi: 10.1038/ng0692-218. [DOI] [PubMed] [Google Scholar]
  19. Hung A. Y., Selkoe D. J. Selective ectodomain phosphorylation and regulated cleavage of beta-amyloid precursor protein. EMBO J. 1994 Feb 1;13(3):534–542. doi: 10.1002/j.1460-2075.1994.tb06291.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ida N., Hartmann T., Pantel J., Schröder J., Zerfass R., Förstl H., Sandbrink R., Masters C. L., Beyreuther K. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem. 1996 Sep 13;271(37):22908–22914. doi: 10.1074/jbc.271.37.22908. [DOI] [PubMed] [Google Scholar]
  21. Iwatsubo T., Mann D. M., Odaka A., Suzuki N., Ihara Y. Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann Neurol. 1995 Mar;37(3):294–299. doi: 10.1002/ana.410370305. [DOI] [PubMed] [Google Scholar]
  22. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron. 1994 Jul;13(1):45–53. doi: 10.1016/0896-6273(94)90458-8. [DOI] [PubMed] [Google Scholar]
  23. Iwatsubo T., Saido T. C., Mann D. M., Lee V. M., Trojanowski J. Q. Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Am J Pathol. 1996 Dec;149(6):1823–1830. [PMC free article] [PubMed] [Google Scholar]
  24. Jarrett J. T., Berger E. P., Lansbury P. T., Jr The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993 May 11;32(18):4693–4697. doi: 10.1021/bi00069a001. [DOI] [PubMed] [Google Scholar]
  25. Kametani F., Tanaka K., Tokuda T., Ikeda S. Secretory cleavage site of Alzheimer amyloid precursor protein is heterogeneous in Down's syndrome brain. FEBS Lett. 1994 Sep 5;351(2):165–167. doi: 10.1016/0014-5793(94)00851-5. [DOI] [PubMed] [Google Scholar]
  26. Kosaka T., Imagawa M., Seki K., Arai H., Sasaki H., Tsuji S., Asami-Odaka A., Fukushima T., Imai K., Iwatsubo T. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Neurology. 1997 Mar;48(3):741–745. doi: 10.1212/wnl.48.3.741. [DOI] [PubMed] [Google Scholar]
  27. Lalowski M., Golabek A., Lemere C. A., Selkoe D. J., Wisniewski H. M., Beavis R. C., Frangione B., Wisniewski T. The "nonamyloidogenic" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. J Biol Chem. 1996 Dec 27;271(52):33623–33631. doi: 10.1074/jbc.271.52.33623. [DOI] [PubMed] [Google Scholar]
  28. Lemere C. A., Blusztajn J. K., Yamaguchi H., Wisniewski T., Saido T. C., Selkoe D. J. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis. 1996 Feb;3(1):16–32. doi: 10.1006/nbdi.1996.0003. [DOI] [PubMed] [Google Scholar]
  29. Levy E., Carman M. D., Fernandez-Madrid I. J., Power M. D., Lieberburg I., van Duinen S. G., Bots G. T., Luyendijk W., Frangione B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science. 1990 Jun 1;248(4959):1124–1126. doi: 10.1126/science.2111584. [DOI] [PubMed] [Google Scholar]
  30. Luyendijk W., Bots G. T., Vegter-van der Vlis M., Went L. N., Frangione B. Hereditary cerebral haemorrhage caused by cortical amyloid angiopathy. J Neurol Sci. 1988 Jul;85(3):267–280. doi: 10.1016/0022-510x(88)90186-4. [DOI] [PubMed] [Google Scholar]
  31. Maruyama K., Usami M., Yamao-Harigaya W., Tagawa K., Ishiura S. Mutation of Glu693 to Gln or Val717 to Ile has no effect on the processing of Alzheimer amyloid precursor protein expressed in COS-1 cells by cDNA transfection. Neurosci Lett. 1991 Oct 28;132(1):97–100. doi: 10.1016/0304-3940(91)90442-v. [DOI] [PubMed] [Google Scholar]
  32. Miller D. L., Papayannopoulos I. A., Styles J., Bobin S. A., Lin Y. Y., Biemann K., Iqbal K. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys. 1993 Feb 15;301(1):41–52. doi: 10.1006/abbi.1993.1112. [DOI] [PubMed] [Google Scholar]
  33. Pepys M. B., Hawkins P. N., Booth D. R., Vigushin D. M., Tennent G. A., Soutar A. K., Totty N., Nguyen O., Blake C. C., Terry C. J. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature. 1993 Apr 8;362(6420):553–557. doi: 10.1038/362553a0. [DOI] [PubMed] [Google Scholar]
  34. Pike C. J., Overman M. J., Cotman C. W. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem. 1995 Oct 13;270(41):23895–23898. doi: 10.1074/jbc.270.41.23895. [DOI] [PubMed] [Google Scholar]
  35. Prelli F., Levy E., van Duinen S. G., Bots G. T., Luyendijk W., Frangione B. Expression of a normal and variant Alzheimer's beta-protein gene in amyloid of hereditary cerebral hemorrhage, Dutch type: DNA and protein diagnostic assays. Biochem Biophys Res Commun. 1990 Jul 16;170(1):301–307. doi: 10.1016/0006-291x(90)91274-v. [DOI] [PubMed] [Google Scholar]
  36. Roher A. E., Lowenson J. D., Clarke S., Wolkow C., Wang R., Cotter R. J., Reardon I. M., Zürcher-Neely H. A., Heinrikson R. L., Ball M. J. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem. 1993 Feb 15;268(5):3072–3083. [PubMed] [Google Scholar]
  37. Roher A. E., Palmer K. C., Yurewicz E. C., Ball M. J., Greenberg B. D. Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J Neurochem. 1993 Nov;61(5):1916–1926. doi: 10.1111/j.1471-4159.1993.tb09834.x. [DOI] [PubMed] [Google Scholar]
  38. Sahasrabudhe S. R., Spruyt M. A., Muenkel H. A., Blume A. J., Vitek M. P., Jacobsen J. S. Release of amino-terminal fragments from amyloid precursor protein reporter and mutated derivatives in cultured cells. J Biol Chem. 1992 Dec 15;267(35):25602–25608. [PubMed] [Google Scholar]
  39. Saido T. C., Iwatsubo T., Mann D. M., Shimada H., Ihara Y., Kawashima S. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron. 1995 Feb;14(2):457–466. doi: 10.1016/0896-6273(95)90301-1. [DOI] [PubMed] [Google Scholar]
  40. Saido T. C., Yamao-Harigaya W., Iwatsubo T., Kawashima S. Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci Lett. 1996 Sep 13;215(3):173–176. doi: 10.1016/0304-3940(96)12970-0. [DOI] [PubMed] [Google Scholar]
  41. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T. D., Hardy J., Hutton M., Kukull W. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996 Aug;2(8):864–870. doi: 10.1038/nm0896-864. [DOI] [PubMed] [Google Scholar]
  42. Selkoe D. J. Alzheimer's disease: genotypes, phenotypes, and treatments. Science. 1997 Jan 31;275(5300):630–631. doi: 10.1126/science.275.5300.630. [DOI] [PubMed] [Google Scholar]
  43. Selkoe D. J. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol. 1994;10:373–403. doi: 10.1146/annurev.cb.10.110194.002105. [DOI] [PubMed] [Google Scholar]
  44. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., Swindlehurst C. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature. 1992 Sep 24;359(6393):325–327. doi: 10.1038/359325a0. [DOI] [PubMed] [Google Scholar]
  45. Suzuki N., Cheung T. T., Cai X. D., Odaka A., Otvos L., Jr, Eckman C., Golde T. E., Younkin S. G. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994 May 27;264(5163):1336–1340. doi: 10.1126/science.8191290. [DOI] [PubMed] [Google Scholar]
  46. Tabaton M., Nunzi M. G., Xue R., Usiak M., Autilio-Gambetti L., Gambetti P. Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun. 1994 May 16;200(3):1598–1603. doi: 10.1006/bbrc.1994.1634. [DOI] [PubMed] [Google Scholar]
  47. Tamaoka A., Kalaria R. N., Lieberburg I., Selkoe D. J. Identification of a stable fragment of the Alzheimer amyloid precursor containing the beta-protein in brain microvessels. Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1345–1349. doi: 10.1073/pnas.89.4.1345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Tamaoka A., Odaka A., Ishibashi Y., Usami M., Sahara N., Suzuki N., Nukina N., Mizusawa H., Shoji S., Kanazawa I. APP717 missense mutation affects the ratio of amyloid beta protein species (A beta 1-42/43 and a beta 1-40) in familial Alzheimer's disease brain. J Biol Chem. 1994 Dec 30;269(52):32721–32724. [PubMed] [Google Scholar]
  49. Teplow D. B. Structural and kinetic features of amyloid beta-protein fibrillogenesis. Amyloid. 1998 Jun;5(2):121–142. doi: 10.3109/13506129808995290. [DOI] [PubMed] [Google Scholar]
  50. Timmers W. F., Tagliavini F., Haan J., Frangione B. Parenchymal preamyloid and amyloid deposits in the brains of patients with hereditary cerebral hemorrhage with amyloidosis--Dutch type. Neurosci Lett. 1990 Oct 16;118(2):223–226. doi: 10.1016/0304-3940(90)90632-j. [DOI] [PubMed] [Google Scholar]
  51. Van Nostrand W. E., Melchor J. P., Ruffini L. Pathologic amyloid beta-protein cell surface fibril assembly on cultured human cerebrovascular smooth muscle cells. J Neurochem. 1998 Jan;70(1):216–223. doi: 10.1046/j.1471-4159.1998.70010216.x. [DOI] [PubMed] [Google Scholar]
  52. Verbeek M. M., de Waal R. M., Schipper J. J., Van Nostrand W. E. Rapid degeneration of cultured human brain pericytes by amyloid beta protein. J Neurochem. 1997 Mar;68(3):1135–1141. doi: 10.1046/j.1471-4159.1997.68031135.x. [DOI] [PubMed] [Google Scholar]
  53. Vigo-Pelfrey C., Lee D., Keim P., Lieberburg I., Schenk D. B. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem. 1993 Nov;61(5):1965–1968. doi: 10.1111/j.1471-4159.1993.tb09841.x. [DOI] [PubMed] [Google Scholar]
  54. Walsh D. M., Lomakin A., Benedek G. B., Condron M. M., Teplow D. B. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem. 1997 Aug 29;272(35):22364–22372. doi: 10.1074/jbc.272.35.22364. [DOI] [PubMed] [Google Scholar]
  55. Watson D. J., Lander A. D., Selkoe D. J. Heparin-binding properties of the amyloidogenic peptides Abeta and amylin. Dependence on aggregation state and inhibition by Congo red. J Biol Chem. 1997 Dec 12;272(50):31617–31624. doi: 10.1074/jbc.272.50.31617. [DOI] [PubMed] [Google Scholar]
  56. Wisniewski T., Ghiso J., Frangione B. Peptides homologous to the amyloid protein of Alzheimer's disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril formation. Biochem Biophys Res Commun. 1991 Sep 30;179(3):1247–1254. doi: 10.1016/0006-291x(91)91706-i. [DOI] [PubMed] [Google Scholar]
  57. Yankner B. A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 1996 May;16(5):921–932. doi: 10.1016/s0896-6273(00)80115-4. [DOI] [PubMed] [Google Scholar]
  58. Zhong Z., Higaki J., Murakami K., Wang Y., Catalano R., Quon D., Cordell B. Secretion of beta-amyloid precursor protein involves multiple cleavage sites. J Biol Chem. 1994 Jan 7;269(1):627–632. [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES